Tyrosine Kinase Inhibitors in Clinical Practice: Case Reports
|
|
- Nicholas Jones
- 6 years ago
- Views:
Transcription
1 european urology supplements 7 (2008) available at journal homepage: Tyrosine Kinase Inhibitors in Clinical Practice: Case Reports Vincenzo Ficarra a, *, Antonio Galfano a, Marco Cosentino a, Manfred Johannsen b a Clinica Urologica, Dipartimento di Scienze Oncologiche e Chirurgiche, Università degli Studi di Padova, Padua, Italy b Department of Urology, Campus Mitte, Charité-Universitätsmedizin Berlin, Germany Article info Keywords: Metastases Multitargeted Renal cell carcinoma Sunitinib malate Tyrosine kinase inhibitor This paper summarizes a presentation at a Pfizersponsored satellite symposium at the European Association of Urology (EAU) Congress on March 27, Abstract Context: Sunitinib malate is an oral, multitargeted receptor tyrosine kinase inhibitor approved multinationally for the treatment of metastatic renal cell carcinoma (mrcc). Objective: Experience of sunitinib use in clinical practice is demonstrated using real-life examples. Evidence acquisition: The use of sunitinib in two representative patients with mrcc is described. Evidence synthesis: The first patient, classified as intermediate risk according to the Memorial Sloan-Kettering Cancer Center (MSKCC) prognostic criteria, was treated with sunitinib following the occurrence of multiple soft-tissue and lung metastases. After 12 mo of follow-up, despite no reduction in the size of the metastases, the contrast enhancement was lower and patient s symptoms had resolved. Increased hypertension was effectively managed using antihypertensive treatment, and no dose reductions were required. The second patient, stratified into the MSKCC poor risk category, had synchronous multiple liver metastases and received sunitinib as a firstline treatment. After 13 mo, a partial response was achieved with minimal toxicity. Adverse events observed included grade 1 diarrhea and grade1/2 hand foot syndrome. No sunitinib dose reductions were required. In addition, the patient reported improvements in quality of life. Conclusions: The case studies reported in this paper confirm the effectiveness of sunitinib for the treatment of patients with mrcc stratified into different risk groups, with manageable adverse events. There is a need for additional stratification tools and new definitions for tumor responses for the new targeted therapies. # 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Corresponding author. Clinica Urologica, Dipartimento di Scienze Oncologiche e Chirurgiche, Università degli Studi di Padova, via Giustiniani, Padua, Italy. Tel ; Fax: address: vincenzo.ficarra@unipd.it (V. Ficarra) /$ see front matter # 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eursup
2 european urology supplements 7 (2008) Introduction Sunitinib malate (Sutent) is an oral, multitargeted receptor tyrosine kinase inhibitor targeting the major subtypes of the vascular endothelial growth factor receptor (VEGFR1, 2, and 3), platelet-derived growth factor receptor (PDGFR-a and -b), stem cell factor receptor (c-kit), colony stimulating factor receptor type 1 (CSF-1R), FMS-like tyrosine kinase-3 receptor (FLT3), and the glial cell-line derived neurotrophic factor receptor (RET) [1 5]. Sunitinib has demonstrated clinical activity in metastatic renal cell carcinoma (mrcc), including in patients with spinal cord compression resulting from mrcc [6], and is the reference standard of care for the first-line treatment of mrcc [7]. Sunitinib is approved multinationally for the treatment of advanced renal cell carcinoma (RCC) and/or mrcc [7]. The development of several targeted agents demonstrating clinical efficacy for the treatment of mrcc highlights the importance selecting the appropriate treatments for individual patients. Prognostic factors that affect treatment outcome allow patients with mrcc to be stratified into risk groups. Several prognostic algorithms can be used to estimate the cancer-specific survival or diseasefree survival in RCC [8,9]. TheStageSizeGradeand Necrosis (SSIGN) score is able to accurately stratify patients with localized clear-cell RCC according to different possible outcomes and to assess the risk of developing metastatic disease [10,11]. The Memorial Sloan-Kettering Cancer Center (MSKCC) [12] model can also be used to stratify patients into favorable, intermediate, and poor risk groups. This stratification model is used for patients with metastatic disease. Treatment can then be optimized according to the patient s risk. Sunitinib is recommended as first-line therapy for patients with mrcc who are considered to be at favorable or intermediate risk [13]. For patients with poor prognosis, temsirolimus is recommended based on the results of a phase 3 trial [11], and sunitinib may also be considered [14]. In this paper, we describe the use of sunitinib in two patients with mrcc. The first patient, stratified into the intermediate MSKCC risk category, was treated with sunitinib following the occurrence of multiple soft-tissue and lung metastases. The second patient was considered at poor prognostic risk, had synchronous multiple liver metastases, and was treated successfully with sunitinib in the first-line setting. 2. Case report 1 The subject was a 57-yr-old woman without significant comorbidities, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0, and hematuria (S2). She presented with a renal mass on the right kidney on a chest and abdominal computed tomography (CT) scan. The renal mass was 10 cm in size and without adrenal or lymph node involvement. No distant metastases were detected, and the contralateral kidney presented as normal. Open radical nephrectomy was successfully performed. Histologic examination revealed clearcell RCC with perirenal fat and adrenal gland invasion (pt3a N0 M0), Fuhrman nuclear grade IV, and coagulative necrosis. Based on a SSIGN score of 9, the patient was deemed to be at high risk of developing metastases. In accordance with the current guidelines, no adjuvant systemic therapy was administered and the patient was monitored at 6-mo intervals with abdominal CT scans and chest x-rays. At the 24-mo postnephrectomy follow-up, the patient presented with multiple soft-tissue and lung metastases. Analysis of risk factors by MSKCC risk stratification revealed corrected serum calcium levels of 12 mg/dl, hemoglobin of 10 g/dl, lactate dehydrogenase (LDH) levels of 180 U/l, and a Karnofsky performance status (PS) of In addition, the time from diagnosis to systemic treatment was longer than 12 mo. Based on these factors, the patient was stratified into the intermediate prognostic risk category and started on sunitinib at 50 mg per day on schedule 4/2 (6-wk cycles of 4 wk on treatment followed by 2 wk off treatment). After eight cycles of sunitinib treatment, tumors in both the soft tissue and the lungs remained unchanged in size; however, the contrast enhancement was lower for both sites (Fig. 1). The patient experienced an improvement in disease-related symptoms, and her anemia resolved. During treatment, grade 1 leukopenia, diarrhea, and petechial bleeding occurred. No sunitinib dose reductions were required, however, and the diarrhea symptoms were managed by using antidiarrheal medication. Increased hypertension was controlled using antihypertensive treatment (an angiotensin-converting enzyme [ACE] inhibitor and b-blocker) during the sunitinib dosing cycles. Initial treatment with b-blockers was unable to effectively manage increased blood pressure, and the patient was switched to treatment with ACE inhibitors. This treatment, combined with antihypertensive treat-
3 612 european urology supplements 7 (2008) Fig. 1 Chest x-ray and computed tomography (CT) scan of metastases in (a) the lungs and (b) soft tissue at initial diagnosis and at 12-mo follow-up. ment during sunitinib treatment cycles, was able to effectively control hypertension and allow the patient to remain on sunitinib therapy. At the next 12-mo follow-up, the patient had stable metastases but contrast enhancement of the tumors was lower; therefore, it was difficult to determine whether the patient achieved a partial response or stable disease as defined by both Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) criteria. Response to therapy is evaluated in most clinical studies using the RECIST criteria developed in the era of cytokine therapy. Other criteria also used in clinical studies to evaluate response include the WHO criteria. Because targeted therapies are antiangiogenic agents that do not act in a cytotoxic capacity, these criteria may not be the most suitable for assessing response to treatment with targeted agents. Our conclusion was that the patient achieved a partial response. The response observed in this case confirms clinical efficacy of sunitinib in the treatment of patients stratified into the intermediate risk category. In addition, the adverse events experienced by the patient were mild to moderate in intensity and easily managed. This case highlights the need for alternative tools for assessing response to targeted therapy. 3. Case report 2 A 63-yr-old male patient presented with symptoms of fever and weight loss (S3), hypertension (Charlson score 1), and ECOG PS of 0. Chest and abdominal CT scans revealed a right renal mass, 7 cm in size, with renal vein involvement. No lymph nodes were involved, and the contralateral kidney was normal. The patient also had synchronous multiple liver metastases. Following open cytoreductive radical nephrectomy, the tumor was identified as clear-cell RCC with sarcomatoid differentiation. The primary tumor extended to the perirenal fat and the renal vein. One of the 20 lymph nodes removed during extended paracaval and interaortocaval lymphadenectomy was also positive for metastatic disease (ct3b N1 M1). The Fuhrman nuclear grade was IV, and coagulative necrosis was present. The patient achieved a SSIGN score of 15, suggesting a poor prognosis in terms of cancer-specific survival. MSKCC risk factor analysis revealed corrected serum calcium levels of 9.3 mg/dl, hemoglobin 9.5 g/dl, LDH 180 U/l and Karnofsky PS of 70 80, with a time from diagnosis to systemic treatment of <12 mo, suggesting that the patient could be stratified into the poor risk category.
4 european urology supplements 7 (2008) (from 10 cm to 6 cm). Further regression of metastases (from 6 cm to 2.5 cm) occurred after a total of 10 mo of treatment with sunitinib (Fig. 2). The patient experienced grade 1 leucopenia, diarrhea, and petechial bleeding. Grade 1/2 hand foot syndrome was also observed, but no sunitinib dose reductions were required. The hand foot syndrome was managed through effective pedicures and local painkillers as well as the use of moisturizing lotion, cotton socks, and soft shoes. Despite unfavorable histology (sarcomatoid differentiation) and poor prognosis, this patient achieved a partial response. The patient has been receiving sunitinib for 13 mo with minimal toxicity. The patient s quality of life, evaluated by means of the Short Form-36 (SF-36) health survey questionnaire at the start of treatment, remains similar to that recorded at treatment initiation in both the emotional and the physical domains. 4. Conclusions Sunitinib has demonstrated clinical efficacy in the treatment of patients with mrcc and is generally well tolerated with most adverse events being grade 1 or 2 in intensity. The case studies reported in this paper confirm the effectiveness of sunitinib for the treatment of mrcc with manageable adverse events such that no dose reduction or interruptions were required. In addition, the cases reported in this paper demonstrate that sunitinib may be used in patients with differing prognostic-risk-factor profiles, including those stratified into the MSKCC poor risk group. The new targeted therapies appear to act differently on tumors compared to chemotherapy or cytokines. As a result, there is a need for new definitions for tumor responses for the new targeted therapies, as highlighted in case report 1. Conflicts of interest Fig. 2 Regression of liver metastases following treatment with sunitinib at 50 mg per day in a patient stratified into the Memorial Sloan-Kettering Cancer Center category for poor risk. The patient was considered to be a suitable candidate for first-line systemic therapy, and sunitinib 50 mg per day (schedule 4/2) was initiated. After 3 mo of treatment with sunitinib, there was significant regression of liver metastases Vincenzo Ficarra has received honoraria from Pfizer Inc. Manfred Johannsen has received honoraria from Bayer Pharmaceuticals, Pfizer Inc, and Sanofi-Aventis. No conflicts of interest were declared by Antonio Galfano and Marco Cosentino. Funding support Pfizer Inc. provided funding for editorial assistance.
5 614 european urology supplements 7 (2008) Acknowledgements The authors acknowledge ACUMED (Tytherington, UK) for providing editorial assistance for this paper. References [1] Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2: [2] Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91: [3] Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9: [4] Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20: [5] O Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101: [6] Trinh Q-D, Cardinal E, Gallina A, Perrotte P, Saad F, Karakiewicz PI. Sunitinib relieves renal cell carcinoma spinal cord compression. Eur Urol 2007;51: [7] Sutent, summary of product characteristics. New York, NY: Pfizer Inc; [8] Ficarra V, Galfano A, Novara G, et al. Risk stratification and prognostication of renal cell carcinoma. World J Urol 2008;26: [9] Karakiewicz PI, Trinh Q-D, Bhojani N, et al. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of diseasespecific survival. Eur Urol 2007;51: [10] Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168: [11] Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003;97: [12] Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20: [13] Ljungberg B, Hanbury DC, Kuczyk MA, et al. Renal cell carcinoma guideline. Eur Urol 2007;51: [14] Gore M. Sunitinib in metastatic renal cell carcinoma (mrcc): preliminary assessment of toxicity in an expanded open access trial with subpopulation analysis. J Clin Oncol 2007;25:237S.
Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will Be Used?
european urology supplements 8 (2009) 478 482 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors: Does It Really Matter if New Drugs for Targeted Therapy Will
More informationeuropean urology 55 (2009)
european urology 55 (2009) 1430 1439 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic
More informationPROGNOSTIC FACTORS FOR SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH CHEMOTHERAPY
Journal of IMAB ISSN: 1312-773X http://www.journal-imab-bg.org http://dx.doi.org/10.5272/jimab.2016221.1045 Journal of IMAB - Annual Proceeding (Scientific Papers) 2016, vol. 22, issue 1 PROGNOSTIC FACTORS
More informationContinued Progress in the Treatment of Advanced Renal Cell Carcinoma: An Update on the Role of Sunitinib
european urology supplements 7 (2008) 579 584 available at www.sciencedirect.com journal homepage: www.europeanurology.com Continued Progress in the Treatment of Advanced Renal Cell Carcinoma: An Update
More informationSequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis
available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationRenal Cell Cancer. Clinical case study 1 & 2. Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland
Renal Cell Cancer Clinical case study 1 & 2 Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland 1 Case study 1 - RCC and Lung Metastases Case study 1: Patient History Male, 63 years old Mild
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationAngiogenesis Targeted Therapies in Renal Cell Carcinoma
Angiogenesis Targeted Therapies in Renal Cell Carcinoma John S. Lam, MD Department of Urology David Geffen School of Medicine University of California-Los Angeles Patient Case CC: Abdominal pain VS: T
More informationeuropean urology 52 (2007)
european urology 52 (2007) 1428 1437 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Platelet Count and Preoperative Haemoglobin Do Not Significantly Increase
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationGUIDELINES ON RENAL CELL CARCINOMA
GUIDELINES ON RENAL CELL CARCINOMA B. Ljungberg (chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction This EAU guideline was prepared to help urologists
More informationeuropean urology 53 (2008)
european urology 53 (2008) 376 381 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients
More informationCharacterization of Patients with Poor-
Characterization of Patients with Poor- Risk Metastatic Renal Cell Carcinoma Hamieh L 1 *, McKay RR 1 *, Lin X 2, Simantov R 2, Choueiri TK 1 *Equal contributions 1 Dana-Farber Cancer Institute, Boston,
More informationThe Role of Multitargeted Therapies in the Adjuvant Setting in Renal Cell Carcinoma
european urology supplements 7 (2008) 63 70 available at www.sciencedirect.com journal homepage: www.europeanurology.com The Role of Multitargeted Therapies in the Adjuvant Setting in Renal Cell Carcinoma
More informationClinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma
european urology supplements 7 (2008) 593 600 available at www.sciencedirect.com journal homepage: www.europeanurology.com Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced
More informationGuidelines on Renal Cell
Guidelines on Renal Cell Carcinoma (Text update March 2009) B. Ljungberg (Chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction Renal cell carcinoma
More informationAdjuvant Therapy in Renal Cell Carcinoma: Where Are We?
european urology supplements 6 (2007) 492 498 available at www.sciencedirect.com journal homepage: www.europeanurology.com Adjuvant Therapy in Renal Cell Carcinoma: Where Are We? Tim Eisen * University
More informationCANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: /
CANCER UROLOGY 3 6 VOL. The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationDebate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.
Debate: Lymphadenectomy is Important in mrcc, CON P. Mulder, M.D., Ph.D. JJ. Patard, MD, Ph.D.. Eighth European International Kidney Cancer Symposium Budapest 03-04 May 2013 The role of LND In organ confined
More informationPrognostic Factors and Staging Systems for Renal Cell Carcinoma
european urology supplements 6 (2007) 623 629 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prognostic Factors and Staging Systems for Renal Cell Carcinoma Vincenzo Ficarra
More informationSurgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 23 March 2012, Sao Paulo, Brazil Surgery of RCC Locally confined (small) renal tumours Locally advanced disease Metastatic
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationIto et al. BMC Cancer 2012, 12:337
Ito et al. BMC Cancer 212, 12:337 RESEARCH ARTICLE Open Access C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from
More informationSurgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense?
Surgical Management of Metastatic and Locally Recurrent Kidney Cancer: Does it Make Sense? Philippe E. Spiess, MD, FACS Associate Member Department of GU Oncology Department of Tumor Biology Moffitt Cancer
More informationA Review in the Treatment Options for Renal Cell Cancer
A Review in the Treatment Options for Renal Cell Cancer Ali McBride, PharmD, MS BCPS, BCOP Clinical Coordinator Hematology/Oncology Department of Pharmacy The University of Arizona Cancer Center RENAL
More informationCLINICAL INVESTIGATION of new agents and combination
Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma By Robert J. Motzer, Jennifer Bacik, Barbara A. Murphy, Paul Russo, and Madhu Mazumdar
More informationSustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma
JOURNAL OF CASE REPORTS 2015;5(1):280-284 Sustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma Chanchal Goswami, Aditi Mandal B. P. Poddar Hospital & Medical Research
More informationREAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO
REAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO Alain Ravaud, MD.PhD Bordeaux. France DISCLOSURES Consultant for: Pfizer, Novartis, GlaxoSmithKline, Roche, Bristol-Myers Squibb Institutional
More informationScottish Medicines Consortium
Scottish Medicines Consortium sorafenib 200mg tablets (Nexavar ) (No. 321/06) Bayer Plc 6 October 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationOncology A Phase II Study of Presurgical Sunitinib in Patients with Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ
Oncology A Phase II Study of Presurgical Sunitinib in Patients with Metastatic Clear-cell Renal Carcinoma and the Primary Tumor In Situ Axel Bex, Christian Blank, Wim Meinhardt, Harm van Tinteren, Simon
More informationVincenzo Ficarra 1,2,3. Associate Editor BJU International
Partial Nephrectomy for RCC Vincenzo Ficarra 1,2,3 1 Director Department of Urology University of Udine, Italy 2 Associate Editor BJU International 3 Scientific Director OLV Robotic Surgery Institute,
More informationLinee guida terapeutiche oncologiche. Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona
Linee guida terapeutiche oncologiche Francesco Massari U.O.C. di Oncologia Medica d.u. Azienda Ospedaliera Universitaria Integrata Verona 1 YOUNG SPECIALIST RENAL CARE Verona, 07-08 Marzo 2014 Clinical
More informationRENAL CANCER GUIDELINES
Greater Manchester and Cheshire Cancer Network RENAL CANCER GUIDELINES Agreed by Urology CSG: July 2010 Review Date: July 2012 Renal Cancer Guidelines 1. Introduction 1.1 Kidney cancer accounts for 3%
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Cabozantinib for untreated locally advanced or metastatic renal cell carcinoma Final scope Remit/appraisal objective To appraise
More informationGUIDELINES ON RENAL CELL CANCER
20 G. Mickisch (chairman), J. Carballido, S. Hellsten, H. Schulze, H. Mensink Eur Urol 2001;40(3):252-255 Introduction is characterised by a constant rise in incidence over the last 50 years, with a predominance
More informationSection Activity Activity Description Details Reference(s)
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with Renal Cell Carcinoma AA Cancer Centre Referrals Not routine pre-op referral indicated
More informationTreatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents
Conflict of Interest Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents None Patrick Medina, PharmD, BCOP Associate Professor University of Oklahoma OKC, OK Learning Objectives Epidemiology
More informationMedical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce
Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationEfficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment
Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment Hisanori Suzuki 1),2), Toshiro Suzuki 1),2), Osamu Ishizuka 1),2), Osamu Nishizawa 1),2),
More informationReference No: Author(s) Approval date: June Committee. Operational Date: July Review:
Reference No: Title: Author(s) Systemic anti-cancer therapy (SACT) guidelines for renal cell cancer Dr Alison Clayton Consultant Medical Oncologist & Dr Jane Hurwitz Consultant Medical Oncologist, Cancer
More information1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.
History and Physical Case Scenario 1 45 year old white male presents with complaints of nausea, weight loss, and back pain. A CT of the chest, abdomen and pelvis was done on 12/8/12 that revealed a 12
More informationPrognostic factors in localized renal cell cancer
Original Article PROGNOSTIC FACTORS IN LOCALIZED RENAL CELL CANCER KNIGHT and STADLER Prognostic factors in localized renal cell cancer David A. Knight and Walter M. Stadler Section of Hematology/Oncology,
More informationUrinary Collecting System Invasion is an Independent Prognostic. Factor in Organ Confined Renal Cell Carcinomas.
Author manuscript, published in "Journal of Urology The 2009;182(3):854-9" DOI : 10.1016/j.juro.2009.05.017 Urinary Collecting System Invasion is an Independent Prognostic Factor in Organ Confined Renal
More informationSunitinib in Patients With Metastatic Renal Cell Carcinoma JAMA. 2006;295:
PRELIMINARY COMMUNICATION Sunitinib in Patients With Metastatic Renal Cell Carcinoma Robert J. Motzer, MD Brian I. Rini, MD Ronald M. Bukowski, MD Brendan D. Curti, MD Daniel J. George, MD Gary R. Hudes,
More informationSAMPLING OF POST NEPHRECTOMY CANCER CARE (5)
SAMPLING OF POST NEPHRECTOMY CANCER CARE (5) Universally recognized post-nephrectomy cancer treatment. Sampling: National Comprehensive Cancer Network (NCCN) NCCN Clinical Practice Guidelines in Oncology
More informationSAMPLE. Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012
Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012 The Renal Cell Carcinoma (RCC) Disease Therapeutics Market GlobalData s analysis suggests
More informationPatient Selection for Surgery in RCC with Thrombus. E. Jason Abel, M.D.
Patient Selection for Surgery in RCC with Thrombus E. Jason Abel, M.D. RCC with venous invasion Venous invasion occurs in ~10% of RCC Surgery more complex Increased risk for morbidity Thrombus may be confined
More informationSynopsis. Study Phase and Title: Study Objectives: Overall Study Design
Synopsis Study Phase and Title: Study Objectives: Overall Study Design Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib
More informationBNC105 Results Presentation
Creating and developing innovative therapies BNC105 Results Presentation Dr Deborah Rathjen CEO & Managing Director, Bionomics Limited Dr José Iglesias Chief Medical Officer, Bionomics Limited Dr Tom Hutson
More informationSurgical Management of Renal Cancer. David Nicol Consultant Urologist
Surgical Management of Renal Cancer David Nicol Consultant Urologist Roles of Surgery 1. Curative intervention localised disease 2. Symptomatic control advanced disease 3. Augmentation of efficacy of systemic
More informationManagement of High Risk Renal Cell Carcinoma
Management of High Risk Renal Cell Carcinoma Peter E. Clark, MD Professor and Chair, Department of Urology Carolinas HealthCare System Chair, Urologic Oncology Levine Cancer Institute October 14, 2017
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More informationRecent Developments in Research on Kidney Cancer: Highlights from Urological and Oncological Congresses in 2007
european urology supplements 7 (2008) 494 507 available at www.sciencedirect.com journal homepage: www.europeanurology.com Recent Developments in Research on Kidney Cancer: Highlights from Urological and
More informationIs There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented by the Revised 7th TNM Version?
EUROPEAN UROLOGY 59 (2011) 258 263 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Is There a Need to Further Subclassify pt2 Renal Cell Cancers as Implemented
More informationA Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma
Kim et al. BMC Urology (2016) 16:46 DOI 10.1186/s12894-016-0163-5 RESEARCH ARTICLE Open Access A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with
More informationSurgeons Perspective: LN as a Draining Pattern. Jose A. Karam, MD, FACS Associate Professor Department of Urology
Surgeons Perspective: LN as a Draining Pattern Jose A. Karam, MD, FACS Associate Professor Department of Urology Disclosures EMD Serono, Pfizer, Novartis: Advisory board/consultant Disclosures I perform
More informationMultidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths
More informationComplex case Presentations
Complex case Presentations Case Presentations April 2016 Lisa M Pickering Case presentations: chromophobe renal carcinoma 60 year old man. ECOG PS 0 No significant comorbodities August 2009: L radical
More informationTreatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria
Treatment Algorithm and Therapy Management in mrcc Manuela Schmidinger Medical University of Vienna Austria A Paradigm Shift in the Treatment of mrcc 1. Sunitinib 2. Sorafenib 3. Bevacizumab+IFN-alpha
More informationSolitary Contralateral Adrenal Metastases after Nephrectomy for Renal Cell Carcinoma
Original Report ISSN 1537-744X; DOI 10.1100/tsw.2004.39 Solitary Contralateral Adrenal after Nephrectomy for Renal Cell Carcinoma Nikolaos Antoniou, M.D. and Demetrios Karanastasis, M.D. General Hospital
More informationAdvanced & Metastatic Renal Cell Carcinoma
Advanced & Metastatic Renal Cell Carcinoma An Update G. Renzulli January 2013 1 Overview of Cancers of the Kidney 2 Global Epidemiology 3 Global Epidemiology of Kidney Cancer 4 Globally, kidney cancer
More informationVincenzo Ficarra. Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine
Best Papers on Kidney Cancer Vincenzo Ficarra Direttore Clinica di Urologia Azienda Ospedaliera Universitaria di Udine Uro-oncological oncological topics Renal Tumor biopsy Positive Surgical Margins after
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationEfficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.5.1971 Efficacy and Toxicity of Sunitinib in Egyptian Patients with Metastatic Renal Cell Carcinoma RESEARCH ARTICLE Efficacy and Toxicity of Sunitinib in Metastatic
More informationLymphadenectomy in RCC: Yes, No, Clinical Trial?
Lymphadenectomy in RCC: Yes, No, Clinical Trial? Viraj Master MD PhD FACS Professor Associate Chair for Clinical Affairs and Quality Director of Clinical Research Unit Department of Urology Emory University
More informationRadiofrequency Ablation of Metastases from Renal Cell Carcinoma: Technique, Complications, and Midterm Outcome
european urology supplements 6 (2007) 653 657 available at www.sciencedirect.com journal homepage: www.europeanurology.com Radiofrequency Ablation of Metastases from Renal Cell Carcinoma: Technique, Complications,
More informationTitle. CitationCancer science, 106(5): Issue Date Doc URL. Rights(URL)
Title Prognosis of Japanese patients with previously untre therapy Shinohara, Nobuo; Obara, Wataru; Tatsugami, Katsunor Author(s) Sachiyo; Abe, Takashige; Oba, Koji; Naito, Seiji CitationCancer science,
More informationOpinion 26 June 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 26 June 2013 VOTRIENT 200 mg, film-coated tablets B/30 (CIP: 491 313 4) VOTRIENT 400 mg, film-coated tablets B/30
More informationKidney Case 1 SURGICAL PATHOLOGY REPORT
Kidney Case 1 Surgical Pathology Report February 9, 2007 Clinical History: This 45 year old woman was found to have a left renal mass. CT urography with reconstruction revealed a 2 cm medial mass which
More informationSPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS
SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS (Filgrastim, Capecitabine, Imatinib, Dasatinib, Erolotinib, Sunitinib, Pazopanib, Fludarabine, Sorafenib, Crizotinib, Tretinoin, Nilotinib,
More informationCanadian Urological Association guidelines for followup of patients after treatment of nonmetastatic
Canadian Urological Association guidelines for followup of patients after treatment of nonmetastatic renal cell carcinoma Wassim Kassouf, Leonardo L. Monteiro, Darrel E. Drachenberg, Adrian S. Fairey,
More informationRenal cell cancer: overview and immunochemotherapy
1 Renal cell cancer: overview and immunochemotherapy Vincent Khoo Introduction and epidemiology Kidney cancer is a relatively common urological cancer, accounting for approximately 2% of all adult cancers.
More informationThe Therapeutic Landscape in Advanced Renal Cell Carcinoma
The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationSunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2013;45(4):349-353 Case Report http://dx.doi.org/10.4143/crt.2013.45.4.349 Open Access Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients
More informationValidation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2017 Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive
More informationPrognostic Value of Renal Vein and Inferior Vena Cava Involvement in Renal Cell Carcinoma
european urology 55 (2009) 452 460 available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Prognostic Value of Renal Vein and Inferior Vena Cava Involvement in Renal
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationHand Foot Skin Reaction is Associated with the Clinical Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib
Original Article Japanese Journal of Clinical Oncology Advance Access published August 15, 2013 Jpn J Clin Oncol doi:10.1093/jjco/hyt110 Hand Foot Skin Reaction is Associated with the Clinical Outcome
More informationInterferon treatment for Japanese patients with favorable-risk metastatic renal cell carcinoma in the era of targeted therapy
Original Article - Urological Oncology Korean J Urol 5;56:5-. http://dx.doi.org/./kju.5.56..5 pissn 5-677 eissn 5-675 Interferon treatment for Japanese patients with favorable-risk metastatic renal cell
More informationMOLECULAR AND CLINICAL ONCOLOGY 7: , 2017
MOLECULAR AND CLINICAL ONCOLOGY 7: 205-210, 2017 Early primary renal tumor response predicts clinical outcome in patients with primary unresectable renal cell carcinoma with synchronous distant metastasis
More informationTratamiento adyuvante y neoadyuvante del cáncer renal en Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet.
Tratamiento adyuvante y neoadyuvante del cáncer renal en 2017 Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet. Barcelona Pronóstico del CR mediante un sistema integrado en 468 pts
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationFeasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
Koie et al. BMC Urology (2015) 15:32 DOI 10.1186/s12894-015-0027-4 RESEARCH ARTICLE Open Access Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution
More informationMetastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy Era
EUROPEAN UROLOGY 56 (2009) 959 971 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Kidney Cancer Metastatic Renal Cell Carcinoma: Recent Advances in the Targeted Therapy
More informationThe incidence and mortality rates of renal cell carcinoma (RCC) have been rising steadily worldwide at a rate of 2% to
Pretreatment Assessment of Tumor Enhancement on Contrast-Enhanced Computed Tomography as a Potential Predictor of Treatment Outcome in Metastatic Renal Cell Carcinoma Patients Receiving Antiangiogenic
More informationCLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY
More information